Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Drug patents in 130+ countries

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Harvard Business School
Express Scripts

Generated: September 22, 2017

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 203147

« Back to Dashboard
NDA 203147 describes RIZATRIPTAN BENZOATE, which is a drug marketed by Glenmark Pharms Ltd, Panacea Biotec Ltd, Cipla Ltd, Sandoz, Jubilant Generics, Unichem Labs Ltd, Invagen Pharms, Apotex Inc, Macleods Pharms Ltd, Eci Pharms Llc, Aurobindo Pharma Ltd, Teva Pharms, Glenmark Generics, Alkem Labs Ltd, Mylan Pharms Inc, Natco Pharma Ltd, and Emcure Pharms Ltd, and is included in twenty-five NDAs. It is available from twenty-six suppliers. Additional details are available on the RIZATRIPTAN BENZOATE profile page.

The generic ingredient in RIZATRIPTAN BENZOATE is rizatriptan benzoate. There are twenty-two drug master file entries for this compound. Thirty suppliers are listed for this compound. Additional details are available on the rizatriptan benzoate profile page.

Summary for NDA: 203147

Therapeutic Class:Antimigraine Agents

Pharmacology for NDA: 203147

Suppliers and Packaging for NDA: 203147

Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
rizatriptan benzoate
TABLET;ORAL 203147 ANDA Macleods Pharmaceuticals Limited 33342-087 33342-087-07 30 TABLET, FILM COATED in 1 CONTAINER (33342-087-07)
rizatriptan benzoate
TABLET;ORAL 203147 ANDA Macleods Pharmaceuticals Limited 33342-087 33342-087-12 10 BLISTER PACK in 1 CARTON (33342-087-12) > 10 TABLET, FILM COATED in 1 BLISTER PACK

Summary for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrengthEQ 5MG BASE
Approval Date:Feb 11, 2014TE:ABRLD:No

Summary for product number 002

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrengthEQ 10MG BASE
Approval Date:Feb 11, 2014TE:ABRLD:No

Complete Access Available with Subscription
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Farmers Insurance
US Army
Argus Health
US Department of Justice
Federal Trade Commission
Daiichi Sankyo
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

Google Plus